Edistride (Dapagliflozin)
SGLT2 Inhibitor for Type 2 Diabetes, Heart Failure & Chronic Kidney Disease
Quick Facts About Edistride
Key Takeaways About Edistride
- Triple indication: Edistride is approved for type 2 diabetes, chronic heart failure (both HFrEF and HFpEF), and chronic kidney disease – benefits extend well beyond blood sugar control
- Cardiovascular protection: Landmark trials (DAPA-HF, DELIVER) showed significant reductions in cardiovascular death and heart failure hospitalisation, regardless of diabetes status
- Renal protection: The DAPA-CKD trial demonstrated that dapagliflozin slows kidney disease progression and reduces the risk of kidney failure
- Watch for genital infections: The most common side effect is genital yeast infections, which are generally mild and treatable but patients should be aware of the symptoms
- DKA awareness: Diabetic ketoacidosis can occur rarely, sometimes with near-normal blood glucose levels – stop Edistride before surgery and during acute illness
What Is Edistride and What Is It Used For?
Edistride (dapagliflozin) is an SGLT2 inhibitor that lowers blood sugar by causing the kidneys to excrete excess glucose in the urine. It is approved for treating type 2 diabetes mellitus, symptomatic chronic heart failure, and chronic kidney disease in adults.
Dapagliflozin belongs to a class of medicines called sodium-glucose co-transporter 2 (SGLT2) inhibitors, sometimes referred to as “gliflozins.” These medicines represent a significant advancement in metabolic and cardiovascular medicine because they target the kidney rather than the pancreas or peripheral tissues. By selectively blocking the SGLT2 protein located in the proximal tubules of the kidneys, dapagliflozin reduces the reabsorption of glucose that has been filtered from the blood. This causes approximately 70 grams of glucose per day to be excreted in the urine, thereby lowering blood glucose levels through a mechanism that is entirely independent of insulin secretion or insulin sensitivity.
The clinical significance of dapagliflozin extends far beyond its glucose-lowering properties. Regulatory agencies including the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have approved dapagliflozin for three distinct indications based on robust clinical trial evidence. First, it is used as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus, either as monotherapy when metformin is not tolerated or as add-on therapy to other glucose-lowering agents including insulin. Second, it is indicated for the treatment of symptomatic chronic heart failure in adults, encompassing both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). Third, it is approved for treating chronic kidney disease (CKD) at risk of progression.
The cardiovascular and renal benefits of dapagliflozin are thought to result from multiple physiological mechanisms beyond glycaemic control. The osmotic diuretic effect reduces blood volume and preload on the heart, while natriuresis (sodium excretion) decreases afterload. The drug also shifts cardiac energy metabolism towards more efficient ketone body utilisation, reduces inflammation and oxidative stress in the kidney, and restores tubuloglomerular feedback, which helps protect kidney function over time. These pleiotropic effects explain why the cardiovascular and renal benefits are observed in patients both with and without diabetes.
In clinical practice, Edistride is typically prescribed alongside other standard-of-care therapies. For diabetes management, it may be combined with metformin, sulphonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, or insulin. For heart failure, it is used in combination with other guideline-directed medical therapies including ACE inhibitors or ARBs (or sacubitril/valsartan), beta-blockers, and mineralocorticoid receptor antagonists. For chronic kidney disease, it serves as an addition to standard treatments including renin-angiotensin system blockade.
Mechanism of Action
Under normal physiological conditions, the kidneys filter approximately 180 grams of glucose from the blood each day, virtually all of which is reabsorbed back into the bloodstream. The SGLT2 transporter is responsible for approximately 90% of this glucose reabsorption. By selectively inhibiting SGLT2, dapagliflozin causes a substantial portion of filtered glucose to remain in the urine and be excreted from the body. This process, called glucosuria, results in a caloric deficit of approximately 200–300 kilocalories per day, which contributes to the modest weight loss observed with SGLT2 inhibitor therapy.
Importantly, the glucose-lowering effect of dapagliflozin diminishes as kidney function declines and less glucose is filtered, which is why the glycaemic benefit is reduced in patients with significantly impaired renal function (eGFR below 45 mL/min/1.73m²). However, the cardiovascular and renal protective effects persist even in patients with low eGFR, which is why dapagliflozin can be initiated and continued for heart failure and CKD indications regardless of eGFR, down to at least 20–25 mL/min/1.73m².
What Should You Know Before Taking Edistride?
Before starting Edistride, your doctor will evaluate your kidney function, blood pressure, and risk factors for diabetic ketoacidosis. Tell your doctor about all medicines you take, any history of urinary tract or genital infections, and whether you are pregnant or breastfeeding.
Contraindications
Edistride must not be taken if you have a known hypersensitivity to dapagliflozin or any of the excipients in the formulation. Allergic reactions, although rare, have been reported and may include skin rash, angioedema, or anaphylaxis. If you experience signs of a serious allergic reaction, stop taking the medicine and seek immediate medical attention.
Dapagliflozin is not indicated for the treatment of type 1 diabetes mellitus. Clinical trials in type 1 diabetes demonstrated an unacceptable increase in diabetic ketoacidosis (DKA) events. The EMA has not approved dapagliflozin for use in type 1 diabetes, and it should not be used off-label for this purpose.
Warnings and Precautions
Several important safety considerations should be discussed with your healthcare provider before starting Edistride:
Rare cases of diabetic ketoacidosis have been reported in patients taking SGLT2 inhibitors, including cases with atypically low blood glucose levels (euglycaemic DKA). Risk factors include a low carbohydrate diet, dehydration, acute illness, surgery, excessive alcohol intake, reduced insulin dose, and history of prior DKA. Stop Edistride at least 3 days before planned elective surgery. If DKA is suspected, discontinue Edistride immediately and seek emergency medical care. Symptoms include nausea, vomiting, abdominal pain, excessive thirst, difficulty breathing, confusion, and unusual fatigue.
Kidney function: Renal function should be assessed before initiating Edistride and monitored periodically thereafter. A transient decrease in eGFR may occur at the start of treatment due to haemodynamic changes in the kidney (a phenomenon known as the “initial dip”), which is generally reversible and considered a marker of renoprotective tubuloglomerular feedback. However, if eGFR declines substantially, temporary discontinuation should be considered. Dapagliflozin may be initiated for heart failure and CKD indications at eGFR values as low as 25 mL/min/1.73m², but the glycaemic efficacy is reduced at lower eGFR levels.
Volume depletion: Dapagliflozin causes osmotic diuresis and may lead to intravascular volume depletion. Symptomatic hypotension may occur, particularly in elderly patients (age 75 years and older), patients with impaired renal function, or patients receiving loop diuretics. Assessment of volume status and correction of any dehydration is recommended before starting treatment. Blood pressure should be monitored during therapy.
Genital and urinary tract infections: SGLT2 inhibitors increase urinary glucose excretion, creating an environment that promotes microbial growth. Genital mycotic infections (candidiasis) are common, especially in women and uncircumcised men. Urinary tract infections may also occur more frequently. Patients with a history of recurrent genital or urinary tract infections should be counselled about the signs and symptoms and treated promptly if infections develop.
Necrotising fasciitis of the perineum (Fournier’s gangrene): Very rare but serious cases of necrotising fasciitis of the perineum have been reported with SGLT2 inhibitors. This is a life-threatening condition requiring urgent surgical intervention. Patients should seek immediate medical attention if they develop pain, tenderness, erythema, or swelling in the genital or perineal area accompanied by fever or malaise.
Lower limb amputation: An increased risk of lower limb amputation has been observed with some SGLT2 inhibitors. Although this risk has not been consistently demonstrated with dapagliflozin in clinical trials, patients with diabetes who have risk factors for amputation (such as prior amputation, peripheral vascular disease, or neuropathy) should be counselled about preventive foot care.
Pregnancy and Breastfeeding
Edistride should not be used during pregnancy. There are no adequate studies of dapagliflozin in pregnant women. Animal studies have shown adverse effects on kidney development and maturation when exposure occurred during periods corresponding to the second and third trimesters of human pregnancy. Dapagliflozin should be discontinued when pregnancy is detected.
It is not known whether dapagliflozin or its metabolites are excreted in human breast milk. A risk to the nursing infant cannot be excluded. Dapagliflozin should not be used during breastfeeding due to the potential for adverse effects on kidney development in the infant.
Women of childbearing potential should use effective contraception during treatment with Edistride. If you are planning to become pregnant, consult your doctor about switching to an alternative treatment with a well-established safety profile during pregnancy.
How Does Edistride Interact with Other Drugs?
Edistride has a relatively favourable drug interaction profile. The most clinically significant interaction is the increased risk of hypoglycaemia when combined with insulin or sulphonylureas, and the increased risk of volume depletion when combined with diuretics.
Dapagliflozin is primarily metabolised through UGT1A9-mediated glucuronidation, which means it is not significantly affected by cytochrome P450 (CYP) enzyme inhibitors or inducers. However, several interactions warrant clinical attention and may require dose adjustments or enhanced monitoring.
| Interacting Drug | Interaction Type | Clinical Significance | Recommendation |
|---|---|---|---|
| Insulin | Increased hypoglycaemia risk | Major | Consider reducing insulin dose by 10–20% when initiating dapagliflozin |
| Sulphonylureas (glimepiride, glipizide, gliclazide) | Increased hypoglycaemia risk | Major | Consider reducing sulphonylurea dose; monitor blood glucose closely |
| Loop diuretics (furosemide, bumetanide) | Additive diuretic/volume depletion effect | Moderate | Monitor for dehydration, hypotension; may need diuretic dose adjustment |
| Thiazide diuretics (hydrochlorothiazide, indapamide) | Additive diuretic effect | Moderate | Monitor hydration status and electrolytes |
| Lithium | Potential change in lithium levels due to diuretic effect | Moderate | Monitor lithium serum levels more frequently |
| Rifampicin | UGT enzyme induction may reduce dapagliflozin exposure | Minor | No dose adjustment required; monitor glycaemic control |
| Pioglitazone | Additive fluid retention risk | Minor | Monitor for signs of fluid retention and heart failure |
| Phenytoin | UGT enzyme induction may reduce dapagliflozin levels | Minor | Monitor glycaemic parameters |
Major Interactions
The most clinically important drug interactions with dapagliflozin involve other glucose-lowering agents that carry a risk of hypoglycaemia. When Edistride is combined with insulin or insulin secretagogues such as sulphonylureas, the risk of low blood sugar is increased. This occurs because dapagliflozin lowers blood glucose through an additional, independent mechanism. Dose reduction of insulin or the sulphonylurea should be considered when initiating dapagliflozin, with regular self-monitoring of blood glucose. Patients should be educated about the signs of hypoglycaemia, including sweating, tremor, hunger, dizziness, and confusion.
The combination of dapagliflozin with loop diuretics such as furosemide or bumetanide requires particular attention due to the additive diuretic and volume-depleting effects. This combination may precipitate symptomatic hypotension, dehydration, or acute kidney injury, especially in elderly patients or those with pre-existing renal impairment. When initiating dapagliflozin in patients already receiving diuretics, careful assessment of volume status and a temporary reduction in diuretic dose may be prudent.
Minor Interactions
Rifampicin, a potent inducer of UGT enzymes, may decrease dapagliflozin exposure by approximately 22%. This reduction is not considered clinically significant and no dose adjustment is required, but glycaemic control should be monitored. Similarly, phenytoin and other UGT enzyme inducers may modestly reduce dapagliflozin levels.
No clinically meaningful pharmacokinetic interactions have been observed between dapagliflozin and commonly co-prescribed medications including metformin, sitagliptin, warfarin, digoxin, or valsartan. Dapagliflozin does not inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, or P-glycoprotein at clinically relevant concentrations.
What Is the Correct Dosage of Edistride?
The recommended dose of Edistride is 10 mg once daily (available as two 5 mg tablets, or as Forxiga 10 mg). For heart failure and CKD, the dose is 10 mg once daily regardless of diabetes status. It may be taken at any time of day, with or without food.
| Indication | Recommended Dose | Special Considerations |
|---|---|---|
| Type 2 Diabetes (monotherapy) | 10 mg once daily | When metformin is not tolerated; assess glycaemic response |
| Type 2 Diabetes (add-on therapy) | 10 mg once daily | Reduce insulin or sulphonylurea dose to lower hypoglycaemia risk |
| Heart Failure (HFrEF and HFpEF) | 10 mg once daily | Use with standard heart failure therapy; benefits regardless of diabetes status |
| Chronic Kidney Disease | 10 mg once daily | May be initiated at eGFR ≥25 mL/min/1.73m²; continue even if eGFR falls below 25 |
Adults
The recommended dose is 10 mg dapagliflozin taken orally once daily. For Edistride 5 mg tablets, this typically means taking two tablets once daily. The tablet should be swallowed whole with a glass of water and may be taken at any time of day, with or without food. Choosing a consistent time each day helps maintain steady drug levels and supports adherence.
For type 2 diabetes, Edistride can be used as monotherapy when metformin is unsuitable or not tolerated, or in combination with other glucose-lowering medicines. When used alongside insulin or sulphonylureas, a reduction in the dose of these concomitant medications should be considered to reduce the risk of hypoglycaemia. The glycaemic effect of dapagliflozin is dependent on renal function, and the glucose-lowering efficacy is reduced in patients with eGFR below 45 mL/min/1.73m².
For heart failure and chronic kidney disease, the dose is 10 mg once daily regardless of diabetes status or eGFR (down to at least 25 mL/min/1.73m² at initiation). Treatment can be continued even if eGFR falls below 25 mL/min/1.73m² during ongoing therapy, as the cardiovascular and renal protective benefits persist.
Children
Edistride is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of dapagliflozin have not been established in paediatric populations. Clinical studies in paediatric patients are limited, and the potential impact on renal maturation and development in growing children remains a concern. Alternative glucose-lowering therapies should be considered for children and adolescents with type 2 diabetes.
Elderly
No dose adjustment is required based on age alone. However, elderly patients (particularly those aged 75 years and older) may be at increased risk of volume depletion-related adverse effects due to the diuretic action of dapagliflozin and the age-related decline in kidney function. Careful monitoring of hydration status, blood pressure, and renal function is recommended. The risk-benefit profile should be carefully evaluated in very elderly patients, and co-administration with diuretics should be approached with caution.
Hepatic Impairment
No dose adjustment is required in patients with mild or moderate hepatic impairment. In severe hepatic impairment, experience is limited; a starting dose of 5 mg is recommended, and if well tolerated, the dose may be increased to 10 mg.
Missed Dose
If you miss a dose of Edistride, take it as soon as you remember on the same day. If the entire day has passed, skip the missed dose and take the next dose at your usual time. Do not take a double dose to make up for the forgotten dose. If you miss several doses, contact your doctor for advice on how to resume treatment.
Overdose
Dapagliflozin has been shown to be safe and well tolerated in healthy individuals at single oral doses up to 500 mg (50 times the recommended dose). Glucose was detected in the urine for a dose-related period of time, but there was no increase in dehydration, hypotension, or electrolyte imbalance. In the event of an overdose, supportive treatment should be initiated as dictated by the patient’s clinical status. Removal of dapagliflozin by haemodialysis has not been studied.
What Are the Side Effects of Edistride?
The most common side effects of Edistride are genital yeast infections, urinary tract infections, and increased urination. Most side effects are mild to moderate and manageable. Serious but rare side effects include diabetic ketoacidosis, severe urinary tract infections, and Fournier’s gangrene.
Like all medicines, Edistride can cause side effects, although not everybody gets them. The side effects observed in clinical trials involving over 15,000 patients are categorised below by their frequency. Understanding the likelihood and nature of side effects helps patients make informed decisions about their treatment and recognise symptoms that may warrant medical attention.
Very Common
- Genital yeast infection (vulvovaginal candidiasis in women, balanitis or balanoposthitis in men)
- Hypoglycaemia (when used with insulin or sulphonylureas)
Common
- Urinary tract infection
- Polyuria (increased urination, including nocturia)
- Back pain
- Dizziness
- Rash
- Dyslipidaemia (increased LDL cholesterol)
- Elevated haematocrit
- Decreased creatinine renal clearance (initial phase)
Uncommon
- Vulvovaginal pruritus (genital itching)
- Fungal infection of the skin
- Thirst
- Constipation
- Dry mouth
- Nocturia (waking at night to urinate)
- Volume depletion (dehydration, hypovolaemia)
- Hypotension
- Raised blood creatinine
- Raised blood urea
Rare
- Diabetic ketoacidosis (DKA)
- Necrotising fasciitis of the perineum (Fournier’s gangrene)
- Severe or complicated urinary tract infection (pyelonephritis, urosepsis)
- Angioedema
- Anaphylaxis
- Tubulointerstitial nephritis
The genital infections associated with dapagliflozin are caused by the increased glucose concentration in the urine, which promotes the growth of Candida species. These infections are more common in women than in men, and more frequent in patients with a history of previous genital infections. Symptoms typically include genital itching, discharge, redness, and discomfort. Most cases are mild to moderate in severity and respond well to standard antifungal treatment. Patients should maintain good genital hygiene and report any symptoms promptly to their healthcare provider.
The increase in urination, including nocturia, is an expected pharmacological effect of the drug resulting from osmotic diuresis. Most patients find that the increased urination stabilises after the first few weeks of treatment. Taking Edistride in the morning rather than the evening may help reduce nocturia. Adequate fluid intake is important, but excessive fluid consumption is generally not necessary.
Contact your doctor or go to the nearest emergency department immediately if you experience: severe abdominal pain with nausea and vomiting (possible DKA); pain, redness, or swelling in the genital or perineal area with fever (possible Fournier’s gangrene); signs of a severe allergic reaction such as facial swelling, difficulty breathing, or widespread skin rash; or signs of severe dehydration such as extreme dizziness, fainting, or very dark urine.
It is important to note that dapagliflozin causes a modest increase in LDL cholesterol, typically in the range of 2–5%. This effect should be considered in the overall cardiovascular risk management of patients. The increase in haematocrit (a measure of red blood cell concentration) is related to the mild haemoconcentration caused by the diuretic effect and is not associated with adverse outcomes. In fact, the haematocrit increase may reflect improved oxygen delivery to tissues, which may contribute to the cardiovascular benefits of the drug.
A transient decrease in eGFR is commonly observed when starting dapagliflozin. This “initial dip” is attributable to haemodynamic changes in the kidney related to the restoration of tubuloglomerular feedback. It is generally reversible and is actually considered a positive prognostic marker for long-term renal protection. However, if the eGFR decline is substantial (more than 30% from baseline) and does not recover, further investigation and possible discontinuation should be discussed with the prescribing physician.
How Should You Store Edistride?
Store Edistride at room temperature below 30°C (86°F) in its original packaging, protected from moisture. Keep out of reach of children.
Edistride tablets should be stored at a temperature not exceeding 30°C (86°F). Keep the tablets in the original blister packaging to protect them from moisture and light. Do not store the tablets in the bathroom, near a kitchen sink, or in other damp, warm environments, as humidity can degrade the medication over time.
Always check the expiry date printed on the blister pack and the outer carton before taking the medicine. Do not use Edistride after the expiry date has passed. Expired medication should be returned to a pharmacy for safe disposal. Do not flush unused medicines down the toilet or throw them in household waste, as this may harm the environment.
Keep Edistride and all medicines out of the sight and reach of children. Store the medicine in a secure location, as accidental ingestion by children or pets could cause adverse effects. If you use a pill organiser, make sure it is also stored in a cool, dry place and out of the reach of children.
What Does Edistride Contain?
Each Edistride 5 mg film-coated tablet contains 5 mg of dapagliflozin (as dapagliflozin propanediol monohydrate) along with inactive ingredients that form the tablet core and coating.
The active substance is dapagliflozin. Each film-coated tablet contains dapagliflozin propanediol monohydrate equivalent to 5 mg of dapagliflozin. Dapagliflozin propanediol monohydrate is a white to off-white crystalline powder that is practically insoluble in water at neutral pH.
The other ingredients (excipients) in the tablet core include: microcrystalline cellulose (E460i), anhydrous lactose, crospovidone (E1202), silicon dioxide (E551), and magnesium stearate (E470b). These excipients serve as fillers, disintegrants, glidants, and lubricants to ensure proper tablet formation, stability, and dissolution.
The film coating contains: polyvinyl alcohol (E1203), titanium dioxide (E171), macrogol 3350 (E1521), talc (E553b), and yellow iron oxide (E172). The film coating provides a protective barrier that aids in swallowing and helps protect the tablet from moisture and light.
Edistride contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Edistride.
Edistride 5 mg tablets are yellow, biconvex, diamond-shaped, approximately 7.5 × 4.5 mm, debossed with “5” on one side and “1427” on the other side. They are available in blister packs of 28 or 98 tablets.
Frequently Asked Questions About Edistride
Edistride and Forxiga both contain the same active substance, dapagliflozin, and are manufactured by the same pharmaceutical company (AstraZeneca). They are therapeutically equivalent products marketed under different brand names in different regions. Forxiga is available in both 5 mg and 10 mg tablets, while Edistride is available as 5 mg tablets. Your doctor will prescribe the appropriate brand and strength based on availability in your country and your specific clinical needs.
Moderate alcohol consumption is generally considered acceptable while taking Edistride, but excessive alcohol intake should be avoided. Heavy alcohol use increases the risk of diabetic ketoacidosis, dehydration, and hypoglycaemia (especially if you also take insulin or sulphonylureas). Alcohol also contributes to dehydration, which can worsen the volume-depleting effect of dapagliflozin. Discuss your alcohol consumption with your doctor to receive personalised guidance.
Edistride can lead to a modest weight reduction of approximately 2–3 kg over the first 6 months, which tends to stabilise thereafter. This occurs because the urinary excretion of approximately 70 grams of glucose per day represents a caloric loss of about 280 kcal daily. However, a compensatory increase in appetite may partially offset this caloric deficit. Edistride is not approved or intended for use as a weight loss medication and should only be taken for its approved indications under medical supervision.
Yes. Edistride should be stopped at least 3 days before scheduled elective surgery. This precaution minimises the risk of diabetic ketoacidosis during the perioperative period, when patients are fasting, under physical stress, and may have altered fluid balance. Your surgeon and anaesthetist should be informed that you are taking an SGLT2 inhibitor. Treatment may be restarted once you are eating and drinking normally and have recovered from surgery. Consult your doctor for specific guidance.
Yes. Edistride is approved for treating chronic kidney disease (CKD) at risk of progression, regardless of whether the patient has diabetes. The DAPA-CKD trial demonstrated that dapagliflozin significantly reduced the risk of a sustained decline in eGFR of at least 50%, end-stage kidney disease, and death from renal or cardiovascular causes. The benefits were consistent across subgroups, including patients with and without type 2 diabetes, and across various causes of CKD such as diabetic nephropathy and IgA nephropathy.
Genital yeast infections are the most common side effect of SGLT2 inhibitors. If you develop symptoms such as itching, burning, redness, or unusual discharge in the genital area, contact your doctor or pharmacist. Most infections respond well to standard over-the-counter antifungal treatments (such as clotrimazole cream or fluconazole oral capsule). Maintaining good hygiene, wearing breathable cotton underwear, and keeping the genital area dry can help prevent recurrence. You do not typically need to stop Edistride because of a genital infection, but discuss this with your doctor if infections become frequent or severe.
References
- McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF). N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303
- Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (DELIVER). N Engl J Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286
- Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD). N Engl J Med. 2020;383(15):1436-1446. doi:10.1056/NEJMoa2024816
- Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes (DECLARE-TIMI 58). N Engl J Med. 2019;380(4):347-357. doi:10.1056/NEJMoa1812389
- European Medicines Agency. Edistride (dapagliflozin) – Summary of Product Characteristics. Last updated 2024.
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes – 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321.
- McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-3639.
- Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2024 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2024;105(4S):S1-S127.
- National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management (NG28). Updated 2024.
- World Health Organization. WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
About the Medical Review
This article has been written and reviewed by the iMedic Medical Editorial Team, composed of licensed specialist physicians in endocrinology, cardiology, nephrology, and clinical pharmacology. All medical claims are based on peer-reviewed research and international clinical guidelines, including the ADA Standards of Care, ESC/EASD Guidelines, KDIGO Guidelines, and NICE recommendations.
Last medical review: . Next scheduled review: . For questions about this content, please contact our medical team.